

Summary

Thalassemia syndromes are genetic disorders in globin chain production, characterized by varying degree of ineffective hematopoiesis and increase hemolysis. Their clinical severity varies widely, ranging from asymptomatic forms to severe or even fatal entities. Genetically Thalassemia represents the most common hereditary hemolytic anemia. It has been estimated that about 1.5% of the global population (80 to 90 million people) are carriers of beta-thalassemia gene, with about 60,000 symptomatic individuals born annually, the great majority in the developing world. β TM has been the most common chronic hemolytic anemia in Egypt with a carrier rate ranging from 5.3% to 10.

Life-long blood transfusion is a standard protocol used for the treatment and care of patients with β -thalassemia major. Although lifesaving, chronic blood transfusion however, results in iron overload with subsequent organ and tissue damages.

Oxidative stress is an important mechanism in the progression of β -TM, whose contribution to β -thalassemic anemia is only partially understood. Oxygen free radicals generation process gains importance because of its role in the pathogenesis of a lot of pathological processes and its effect on mortality and morbidity. Oxygen free radicals cause lipid peroxidation, the end product of lipid peroxidation is MDA. The iron chelator DFO has been used for several decades to prevent iron overload in patients with thalassemia, due to its ability to inhibit the redox activity of transition metals through chelation.

Haptoglobin is an acute phase protein that scavenges hemoglobin in the event of intravascular or extravascular hemolysis and reduces the oxidative and peroxidative potential of free Hb. In human populations three common phenotypes are represented: Hp1-1, Hp2-2 and the heterozygous Hp2-1, which is determined by two alleles Hp1 and Hp2. The unique and peculiar functional activities defined by the phenotypes make consideration of Hp gene polymorphism.

More recently, several functional differences between haptoglobin phenotypes have been demonstrated that appear to have important biological and clinical consequences. Haptoglobin polymorphism is associated with the prevalence and clinical evolution of many inflammatory diseases, including infections, atherosclerosis, and autoimmune disorders. These effects are explained by a phenotype-dependent modulation of oxidative stress and prostaglandin synthesis. The antioxidant role of haptoglobin and the phenotype dependence were confirmed for preventing possible oxidative damage induced by free hemoglobin and iron release during its catabolism.

The aim of the work is to study the impact of haptoglobin gene polymorphism on phenotypic variability in patients with β thalassemia major in relation to iron overload and oxidative stress.

The study was conducted among fifty patients with established β TM, they were on regular RBCs transfusion and all patients were adherent to iron chelation therapy using DFO. Blood samples were collected before blood transfusion, Cases with apparent acute infection were excluded. Twenty five normal apparently healthy individuals of matching age and sex with previous group were served as control. All patients as well control subjects included in the study were subjected to the following:

1. Thorough history taking with special emphasis on patient's age at first presentation, frequency of blood transfusion and chelation therapy and history of operative procedures (splenectomy).)
2. Complete clinical examination with special emphasis on thalassemic manifestations, hepatomegaly, splenomegaly.
3. Laboratory investigations including:
 - a) Routine investigation including
 - Complete Blood Count (CBC), Blood film, Reticulocytes count, Hb electrophoresis.
 - Iron profile (serum iron, total iron binding capacity, transferrin saturation)
 - Serum ferritin, C- reactive protein (CRP) and Coombs' test.
 - b) Special laboratory tests
 - Serum haptoglobin (Hp).
 - Serum malondialdehyde (MDA).
 - Haptoglobin gene polymorphism by PCR.

Data from our study confirm that the decrease of the hemoglobin level in thalassemic group is accompanied by a decrease in the erythrocytes number and by diminished values of their specific indexes (MCV, MCH, PCV, etc.).

The content of mean serum iron ($42.30\mu\text{mol/l}$) and mean serum ferritin ($3287.22\mu\text{g/l}$) were significantly increased above that of the controls in all the patients examined. The study revealed that 32% of thalassemic patients are HCV positive which is higher than the reported prevalence of HCV in Egypt (15-20%). 16% of our patients had a positive antiglobulin test, this is partly attributed to lack of extended phenotyping as a standard routine in our blood banks. In the present study, a significant correlation was found between a positive DAT and a lower serum haptoglobin level ($P=0.017$) being consumed in the trapping free Hb from circulation.

On the other hand, the lower levels of serum haptoglobin in thalassemic patients could be attributed to the presence of different polymorphisms of the haptoglobin gene. Consequently, the genotype Hp1-1 results in the highest level of serum haptoglobin, while Hp2-1 and Hp2-2 are associated with lower serum haptoglobin levels approaching statistical significance ($P=0.067$).

In the present study, 56% of patients had the Hp2-2 genotype, followed by Hp 2—1 genotype, while in the control, Hp2-1 predominated, the study also revealed that thalassemic patients with Hp2-2 have the highest serum ferritin.

In the present study, a significantly higher level of MDA, a marker of lipid peroxidation was found in patients versus the control, ($P < 0.001$) reflecting a state of significant oxidative stress in patients group. The highest level was found in patients with the Hp2-2 phenotype ($P=0.056$) as compared with the other phenotypes.

Therefore, we hypothesize that oxidative stress is a major factor of morbidity in β -thalassemic and is correlated with iron overload and metabolic dysfunctions. We have demonstrated that there are functional differences in the antioxidant capacity of the different haptoglobin proteins toward hemoglobin, suggesting that those with haptoglobin 1-1 protein may have superior antioxidant protection than those with Hp 2-2 protein .

Conclusions

From the above findings we could extrapolate several conclusions:

- Thalassemia patients are at a great risk of oxidative stress.
- Haptoglobin polymorphism and phenotypic variability have a great impact on oxidative stress in thalassemia patients.
- Thalassemia patients with Hp 2-2 phenotype are under greater iron-driven oxidative stress than patients with other phenotypes.
- Despite chelation, they could not achieve the desired threshold of serum ferritin levels possibly due to non-compliance.
- Haptoglobin served as an antioxidant by virtue of its ability to prevent hemoglobin driven oxidative tissue damage.
- The frequency of blood transfusions given per month appears to be inadequate. In terms of pre transfusion hemoglobin levels (taking 9.5 gm% as cut off), 98% of patients are undertransfused.
- In terms of serum ferritin levels (taking 1000 ng/ml as cut off), nearly 94% of patients need their chelation regime to be reviewed.
- To prevent anaphylactic transfusion reactions, distinguishing the *Hp del* allele from the non-deficient allele is most important.

Recommendations

From the findings of the present study, we may recommend the following:

- Determination of haptoglobin phenotype is mandatory to these patients in order to tailor iron chelation therapy, and to detect Hp0 allele.
- MDA should be estimated at least once per year to guide the proper antioxidant therapy.
- Thalassemia patients should receive filtered blood to dampen activated neutrophils and ROS.
- Extended blood group phenotyping is highly warranted to prevent alloimmunization and secondary autoimmunization.
- The study suggests the need to step up the transfusions to achieve pre-transfusion hemoglobin goal of 9.5 gm/dl and also to institute urgent and effective chelation measures with the aim of keeping serum ferritin levels below 1000 ng/ml.

References

1. Thein SL, Rees D. Hemoglobin and the inherited disorders of globin synthesis. In: Postgraduate Hematology. Hoffbrand AV, Catovsky D, Tuddenham EGD, Green AR (eds). 6th ed. Wiley- Blackwell, Chichester. 2011. p.83-107.
2. Weatherall DJ, Clegg JB. The Thalassaemia Syndromes (ed4th). Oxford: Blackwell Science; 2001.
3. Flint J, Harding RM, Boyce AJ, Clegg JB. The population genetics of the haemoglobinopathies. *Baillieres Clin Haematol* 1993; 6:215–62.
4. Hussein IR, EL-Beshlawy A, Aboul-Ezz E, El-Hadidi S, El-Motayam K. Screening for β thalassemia mutations utilizing buccal cells. *Egypt J Paediatr* 2000; 17(1): 139–51.
5. Novelletto A, Hafez M, Deidda G, Di Rienzo A, Felicetti L, EL-Tahan H. Molecular characterization of beta-thalassemia mutations in Egypt. *Hum Genet* 1990; 85(3):272–74.
6. Srinoun K, Svasti S, Chumworathayee W, Vadolas J, Vattanaviboon P, Fucharoen S, et al. Imbalanced globin chain synthesis determines erythroid cell pathology in thalassaemic mice. *Haematologica* 2009; 94(9): 1211–9.
7. Thein SL. Pathophysiology of β Thalassaemia -A Guide to Molecular Therapies. *Am Soc Hematol Educ Program* 2005; 1:31-7.
8. Galanello R, Perseu L, Satta S, Demartis FR, Campus S. Phenotype-genotype correlation in β -thalassaemia. *Thalassaemia Reports* 2011; 1(s2):16-20.
9. Thein SL. Dominant beta thalassaemia: molecular basis and pathophysiology. *Br J Haematol* 1992; 80:273–77.
10. Weatherall D J. Phenotype–genotype relationships in the monogenic diseases: lessons from the thalassaemias. *Nature Review* 2001; 2:245-55.
11. Huisman T H J, Carver M.F H, Baysal E. A syllabus of Thalassaemia Mutations 1–309. The Sickle Cell Anemia Foundation, Augusta, Georgia, 1997.
12. Bianco I, Cappabianca M, Foglietta E, Lerone M, Deidda G, Morlupi L, et al. Silent thalassaemia: Genotypes and phenotypes. *Haematologica* 1997; 82:269–80.
13. Gonzalez-Redondo JM, Stoming TA, Kutlar A, Kutlar F, Lanclos KD, Howard EF, et al. A C---T substitution at nt--101 in a conserved DNA sequence of the promotor region of the beta-globin gene is associated with “silent” beta-thalassaemia. *Blood* 1989; 73:1705-11.
14. Weatherall DJ, Clegg JB, Wood WG, Old JM, Higgs DR, Pressley L, et al. The clinical and molecular heterogeneity of the thalassaemia syndromes. *Ann NY Acad Sci* 1980; 344:83-100.

15. Rees D C, Styles J, Vichinsky EP, Clegg JB, Weatherall DJ. The hemoglobin E syndromes. *Ann NY Acad Sci* 1998; 850:334–43.
16. Kan YW, Nathan DG. Mild thalassemia: the result of interactions of α and β thalassemia genes. *J Clin Invest* 1970; 49: 635–42.
17. Weatherall D J, Pressley L, Wood W G, Higgs DR, Clegg J B. The molecular basis for mild forms of homozygous β thalassaemia. *Lancet* 1981; 317:527–9.
18. Boyer SH, Belding TK, Margolet L, Noyes AN. Fetal hemoglobin restriction to a few erythrocytes (F cells) in normal human adults. *Science* 1975; 188: 361–3.
19. Garner C, Tatu T, Reittie JE, Littelwood T, Darley J, Cervino S, et al. Genetic influences on F cells and other hematologic variables: a twin heritability study. *Blood* 2000; 95:342–6.
20. Labie D, Pagnier J, Lapoumeroulie C, Rouabih F, DundaBelkhodja O, Chardin P, et al. Common haplotype dependency of high γ -globin gene expression and high Hb F levels in β -thalassemia and sickle cell anemia patients. *Proc Natl Acad Sci USA* 1985; 82: 2111–4.
21. Gilman JG, Huisman THJ. DNA sequence variation associated with elevated fetal γ globin production. *Blood* 1985; 66:783–7.
22. Thein S L. International Practice and Research: The Haemoglobinopathies. in: *Baillière's Clinical Haematology*. Higgs D R, Weatherall, D J. Baillière Tindall, London. 1993.151–176.
23. Craig J E, Rochette J, Fisher CA, Weatherall DJ, Marc S, Lathrop GM, et al. Haemoglobin switch: dissecting the loci controlling fetal haemoglobin production on chromosomes 11p and 6q by the regressive approach. *Nature Genet* 1996; 12(1):58–64.
24. Menzel S, Thein SL. Genetic architecture of hemoglobin F control. *Curr Opin Hematol* 2009;16(3):179-86.
25. Dover G J, Smith KD, Chang YC, Purvis S, Mays A, Sheils S, et al. Fetal hemoglobin levels in sickle cell disease and normal individuals are partially controlled by an X-linked gene located at Xp22.2. *Blood* 1992;80(3): 816–24.
26. Goossens M, Mozy AM, Embury SH, Zchariades Z, Hadjiminias MG, Khan YW, et al. Triplicated α -globin loci in humans. *Proc Natl Acad Sci USA* 1980; 77(1):518–21.
27. Kanavakis E, Metaxatou-Mavromati A, Kattamis C, Wainscoat J S, Wood WG. The triplicated α gene locus and β thalassaemia. *Br J Haematol* 1983; 54:201–7.
28. Beris P, Soleuthaler M, Deutsch S, Darbellay R, Tobler A, Gabblani G, et al. Severe inclusion body β -thalassaemia with haemolysis in a patient double heterozygous for β^0 thalassaemia and quadruplicated α -globin gene arrangement of the anti-4.2 type. *Br J Haematol* 1999; 105(4):1074–80.

29. Thein SL. Genetic insights into the clinical diversity of β thalassaemia. *Br J Hematol* 2004; 124:264-74.
30. Galanello R, Perseu L, Melis MA, Cipollina L, Barella S, Giagu N, et al. Hyperbilirubinaemia in heterozygous β -thalassaemia is related to co-inherited Gilbert's syndrome. *Br J Haematol* 1997; 99(2): 433-6.
31. Sampietro, M, Lupica L, Perrero L, Comino A, Martinez di Montemuros F, Cappellini MD, et al. The expression of uridine diphosphateglucuronosyltransferase gene is a major determinant of bilirubin level in heterozygous β -thalassaemia and in glucose-6-phosphate dehydrogenase deficiency. *Br J Haematol* 1997; 99(2):437-9.
32. Rees DC, Singh B M, Luo LY, Wickramasinghe S, Thein S L. Non transfusional iron overload in thalassemia:association with hereditary hemochromatosis. *Ann NY Acad Sci* 1998; 850:490-4.
33. Piperno A, Mariani R, Arosio C, Vergani A, Bosio S, Fargion S, et al. Haemochromatosis in patients with β -thalassaemia trait. *Br J Haematol* 2000; 111(3): 908-14.
34. Merryweather-Clarke AT, Pointon J J, Shearman J D, Robson K J H. Global prevalence of putative haemochromatosis mutations. *J Med Genet* 1997; 34: 275-8.
35. Rees Dc, Singh BM, Luo LY, Wickramasinghe S, Thein SL. Genetic influences on bone disease in thalassemia. *Blood* 1998; 92:S532a.
36. Williams TN, Maitland K, Bennett S, Ganczakowski M, Peto TE, Newbold CI, et al. High incidence of malaria in α - thalassaemic children. *Nature* 1996; 383:522-5.
37. Weatherall DJ, Clegg JB, Kwiatkowski D. The role of genomics in studying genetic susceptibility to infectious disease. *Genome Res* 1997; 7: 967-73.
38. Hill AVS, Allsopp CEM, Kwiatkowski D. Common West African HLA antigens are associated with protection from severe malaria. *Nature* 1991; 352:595-600.
39. McGuire W, Hill AVS, Allsopp CEM, Greenwood B M, Kwiatkowski D. Variation in the TNF- α promoter region associated with susceptibility to cerebral malaria. *Nature* 1994; 37: 508-11.
40. Fernandez-Reyes D, Craig AG, Kyes SA, Peshu N, Snow RW, Berendt AR, et al. A high frequency African coding polymorphism in the N-terminal domain of ICAM-1 predisposing to cerebral malaria in Kenya. *Hum Mol Genet* 1997; 6:1357-60.
41. Weatherall DJ. Thalassemia in the next millennium. *Ann NY Acad Sci* 1998; 850:1-9.
42. Crichton RR, Wilmet S, Legssyer R, Ward RJ. Molecular and cellular mechanisms of iron homeostasis and toxicity in mammalian cell. *J Inorg Biochem* 2002; 9: 9-18.
43. Finch C. Regulators of iron balance in humans. *Blood* 1994; 84:1697-1702.

44. De Domenico I, McVey Ward D, Kaplan J. Regulation of iron acquisition and storage: consequences for iron-linked disorders. *Nat Rev Mol Cell Biol* 2008; 9:72-81.
45. Leimberg MJ, Prus E, Konijn AM, Fibach E. Macrophages function as a ferritin iron source for cultured human erythroid precursors. *J Cell Biochem* 2008; 103:1211-8.
46. Uchida T, Akitsuki T, Kimura H, Tanaka T, Matsuda S, Kariyone S. Relationship among plasma iron, plasma iron turnover, and reticuloendothelial iron release. *Blood* 1983; 61:799-802.
47. Deugnier YM, Loreal O, Turlin B, Guyader D, Jouanolle H, Moirand R, et al. Liver pathology in genetic hemochromatosis: a review of 135 homozygous cases and their biochemical correlations. *Gastroenterology* 1992; 102:2050-9.
48. Piperno A. Classification and diagnosis of iron overload. *Haematologica* 1998; 83:447-55.
49. Hentze MW, Muckenthaler MU, Andrews NC. Balancing acts: molecular control of mammalian iron metabolism. *Cell* 2004; 117:285-97.
50. Bernstein SE. Hereditary hypotransferrinemia with hemosiderosis, a murine disorder resembling human atransferrinemia. *J Lab Clin Med* 1987; 110:690-705.
51. Trombini P, Coliva T, Nemeth E, Mariani R, Ganz T, Biondi A, et al. Effects of plasma transfusion on hepcidin production in human congenital hypotransferrinemia. *Haematologica* 2007; 92:1407-10.
52. West AR, Oates PS. Mechanisms of heme iron absorption: current questions and controversies. *World J Gastroenterol* 2008; 14:4101-10.
53. Inoue K, Nakai Y, Ueda S, Kamigaso S, Ohta KY, Hatakeyama M, et al. Functional characterization of PCFT/HCP1 as the molecular entity of the carrier-mediated intestinal folate transport system in the rat model. *Am J Physiol Gastrointest Liver Physiol* 2008; 294:660-8.
54. Quigley JG, Yang Z, Worthington MT, Phillips JD, Sabo KM, Sabath DE, et al. Identification of a human heme exporter that is essential for erythropoiesis. *Cell* 2004; 118:757-66.
55. Andrews NC. The iron transporter DMT1. *Int J Biochem Cell Biol* 1999; 31:991-4.
56. Ganz T. Cellular iron: ferroportin is the only way out. *Cell Metab* 2005; 1:155-7.
57. Frazer DM, Vulpe CD, McKie AT, Wilkins SJ, Trinder D, Cleghorn GJ, et al. Cloning and gastrointestinal expression of rat hephaestin: relationship to other iron transport proteins. *Am J Physiol Gastrointest Liver Physiol* 2001; 281:931-9.
58. Mariani R, Arosio C, Pelucchi S, Grisoli M, Piga A, Trombini P, Piperno A. Iron chelation therapy in aceruloplasminemia: study of a patient with a novel missense mutation. *Gut* 2004; 53:756-8.

59. Nemeth E, Tuttle MS, Powelson J, Vaughn MB, Donovan A, Ward DM, et al. Heparin regulates cellular iron efflux by binding to ferroportin and inducing its internalization. *Science* 2004; 306:2090-3.
60. De Domenico I, Lo E, Ward DM, Kaplan J. Heparin-induced internalization of ferroportin requires binding and cooperative interaction with Jak2. *Proc Natl Acad Sci USA* 2009; 106:3800-5.
61. De Domenico I, Ward DM, Musci G, Kaplan J. Iron overload due to mutations in ferroportin. *Haematologica* 2006; 91:92-5.
62. Anderson GJ. Non-transferrin-bound iron and cellular toxicity. *J Gastroenterol Hepatol* 1999; 14:105-8.
63. Gunshin H, Fujiwara Y, Custodio AO, Drenth C, Robine S, Andrews NC. Slc11a2 is required for intestinal iron absorption and erythropoiesis but dispensable in placenta and liver. *J Clin Invest* 2005; 115:1258-66.
64. Liuzzi JP, Aydemir F, Nam H, Knutson MD, Cousins RJ. Zip14 (Slc39a14) mediates non-transferrin-bound iron uptake into cells. *Proc Natl Acad Sci USA* 2006; 103:13612-7.
65. Oudit GY, Sun H, Trivieri MG, Koch SE, Dawood F, Ackerley C, et al. L-type Ca²⁺ channels provide a major pathway for iron entry into cardiomyocytes in iron-overload cardiomyopathy. *Nat Med* 2003; 9:1187-94.
66. Mwanjewe J, Grover AK. Role of transient receptor potential canonical 6 (TRPC6) in non-transferrin-bound iron uptake in neuronal phenotype PC12 cells. *Biochem J* 2004; 378:975-82.
67. Piperno A, Mariani R, Trombini P, Girelli D. Heparin modulation in human diseases: from research to clinic. *World J Gastroenterol* 2009; 15:538-51.
68. Nicolas G, Bennoun M, Devaux I, Beaumont C, Grandchamp B, Kahn A, et al. Lack of heparin gene expression and severe tissue iron overload in upstream stimulatory factor 2 (USF2) knockout mice. *Proc Natl Acad Sci USA* 2001; 98:8780-5.
69. Nicolas G, Bennoun M, Porteu A, Mativet S, Beaumont C, Grandchamp B, et al. Severe iron deficiency anemia in transgenic mice expressing liver heparin. *Proc Natl Acad Sci USA* 2002; 99:4596-601.
70. Nemeth E. Iron regulation and erythropoiesis. *Curr Opin Hematol* 2008; 15:169-75.
71. Gao J, Chen J, Kramer M, Tsukamoto H, Zhang AS, Enns CA. Interaction of the hereditary hemochromatosis protein HFE with transferrin receptor 2 is required for transferrin-induced heparin expression. *Cell Metab* 2009; 9:217-27.

72. Pietrangelo A, Caleffi A, Henrion J, Ferrara F, Corradini E, Kulaksiz H, et al. Juvenile hemochromatosis associated with pathogenic mutations of adult hemochromatosis genes. *Gastroenterology* 2005; 128:470-49.
73. Wallace DF, Dixon JL, Ramm GA, Anderson GJ, Powell LW, Subramaniam N. Hemojuvelin (HJV)-associated hemochromatosis: analysis of HJV and HFE mutations and iron overload in three families. *Haematologica* 2005; 90:254-5.
74. Niederkofler V, Salie R, Arber S. Hemojuvelin is essential for dietary iron sensing, and its mutation leads to severe iron overload. *J Clin Invest* 2005; 115:2180-6.
75. Babitt JL, Huang FW, Xia Y, Sidis Y, Andrews NC, Lin HY. Modulation of bone morphogenetic protein signaling in vivo regulates systemic iron balance. *J Clin Invest* 2007; 117:1933-1939.
76. Camaschella C. BMP6 orchestrates iron metabolism. *Nat Genet* 2009; 41:386-388.
77. Wang RH, Li C, Xu X, Zheng Y, Xiao C, Zerfas P, et al. A role of SMAD4 in iron metabolism through the positive regulation of hepcidin expression. *Cell Metab* 2005; 2:399-409.
78. Nemeth E, Rivera S, Gabayan V, Keller C, Taudorf S, Pedersen BK, et al. IL-6 mediates hypoferrremia of inflammation by inducing the synthesis of the iron regulatory hormone hepcidin. *J Clin Invest* 2004; 113:1271-6.
79. Verga Falzacappa MV, Vujic Spasic M, Kessler R, Stolte J, Hentze MW, Muckenthaler MU. STAT3 mediates hepatic hepcidin expression and its inflammatory stimulation. *Blood* 2007; 109:353-8.
80. Peyssonnaud C, Zinkernagel AS, Schuepbach RA, Rankin E, Vaultont S, Haase VH, et al. Regulation of iron homeostasis by the hypoxia-inducible transcription factors (HIFs). *J Clin Invest* 2007; 117:1926-32.
81. Lin L, Goldberg YP, Ganz T. Competitive regulation of hepcidin mRNA by soluble and cell-associated hemojuvelin. *Blood* 2005; 106:2884-9.
82. Silvestri L, Pagani A, Nai A, De Domenico I, Kaplan J, Camaschella C. The serine protease matriptase-2 (TMPRSS6) inhibits hepcidin activation by cleaving membrane hemojuvelin. *Cell Metab* 2008; 8:502-11.
83. Melis MA, Cau M, Congiu R, Sole G, Barella S, Cao A, et al. A mutation in the TMPRSS6 gene, encoding a transmembrane serine protease that suppresses hepcidin production, in familial iron deficiency anemia refractory to oral iron. *Haematologica* 2008; 93:1473-9.
84. Pak M, Lopez MA, Gabayan V, Ganz T, Rivera S. Suppression of hepcidin during anemia requires erythropoietic activity. *Blood* 2006; 108:3730-3735.
85. Vokurka M, Krijt J, Sulc K, Necas E. Hepcidin mRNA levels in mouse liver respond to inhibition of erythropoiesis. *Physiol Res* 2006; 55:667-74.

86. Weizer-Stern O, Adamsky K, Amariglio N, Levin C, Koren A, Breuer W, et al. Downregulation of hepcidin and haemojuvelin expression in the hepatocyte cell-line HepG2 induced by thalassaemic sera. *Br J Haematol* 2006; 135:129-138.
87. Kemna EH, Kartikasari AE, van Tits LJ, Pickkers P, Tjalsma H, Swinkels DW. Regulation of hepcidin: insights from biochemical analyses on human serum samples. *Blood Cells Mol Dis* 2008; 40:339-46.
88. Gardenghi S, Marongiu MF, Ramos P, Guy E, Breda L, Chadburn A, et al. Ineffective erythropoiesis in beta-thalassemia is characterized by increased iron absorption mediated by down-regulation of hepcidin and up-regulation of ferroportin. *Blood* 2007; 109:5027-35.
89. Tanno T, Bhanu NV, Oneal PA, Goh SH, Staker P, Lee YT, et al. High levels of GDF15 in thalassemia suppress expression of the iron regulatory protein hepcidin. *Nat Med* 2007; 13:1096-101.
90. Tanno T, Porayette P, Sripichai O, Noh SJ, Byrnes C, Bhupatiraju A, et al. Identification of TWSG1 as a second novel erythroid regulator of hepcidin expression in murine and human cells. *Blood* 2009; 114:181-6.
91. Smith TG, Robbins PA, Ratcliffe PJ. The human side of hypoxia-inducible factor. *Br J Haematol* 2008; 141:325-34.
92. Choi SO, Cho YS, Kim HL, Park JW. ROS mediate the hypoxic repression of the hepcidin gene by inhibiting C/EBPalpha and STAT-3. *Biochem Biophys Res Commun* 2007; 356:312-7.
93. Shah YM, Matsubara T, Ito S, Yim SH, Gonzalez FJ. Intestinal hypoxia-inducible transcription factors are essential for iron absorption following iron deficiency. *Cell Metab* 2009; 9:152-64.
94. Silvestri L, Pagani A, Camaschella C. Furin-mediated release of soluble hemojuvelin: a new link between hypoxia and iron homeostasis. *Blood* 2008; 111:924-31.
95. Origa R, Galanello R, Ganz T, Giagu N, Maccioni L, Faa G, et al. Liver iron concentrations and urinary hepcidin in beta-thalassemia. *Haematologica* 2007; 92:583-8.
96. Pippard MJ, Callender ST, Warner GT, Weatherall DJ. Iron absorption and loading in beta-thalassaemia intermedia. *Lancet* 1979; 2:819-21.
97. Hershko C, Rachmilewitz EA. Mechanism of desferrioxamine-induced iron excretion in thalassaemia. *Br J Haematol* 1979; 42:125-32.
98. Rivella S. Ineffective erythropoiesis and thalassemias. *Curr Opin Hematol* 2009; 16:187-94.

99. Walter PB, Fung EB, Killilea DW, Jiang Q, Hudes M, Madden J, et al. Oxidative stress and inflammation in iron-overloaded patients with beta-thalassaemia or sickle cell disease. *Br J Haematol* 2006; 135:254-63.
100. Kattamis A, Papassotiriou I, Palaiologou D, Apostolakou F, Galani A, Ladis V, et al. The effects of erythropoietic activity and iron burden on hepcidin expression in patients with thalassemia major. *Haematologica* 2006; 91:809-12.
101. Camberlein E, Zanninelli G, Detivaud L, Lizzi AR, Sorrentino F, Vacquer S, et al. Anemia in beta-thalassemia patients targets hepatic hepcidin transcript levels independently of iron metabolism genes controlling hepcidin expression. *Haematologica* 2008; 93:111-15.
102. Kearney SL, Nemeth E, Neufeld EJ, Thapa D, Ganz T, Weinstein DA, et al. Urinary hepcidin in congenital chronic anemias. *Pediatr Blood Cancer* 2007; 48:57-63.
103. Fibach E, Rachmilewitz E. The role of oxidative stress in hemolytic anemia. *Curr Mol Med* 2008;8: 609–19.
104. Rund D, Rachmilewitz E. Beta-thalassemia. *N Engl J Med* 2005; 353: 1135–46.
105. Rachmilewitz EA, Weizer-Stern O, Adamsky K, Amariglio N, Rechavi G, Breda L, et al. Role of iron in inducing oxidative stress in thalassemia: Can it be prevented by inhibition of absorption and by antioxidants? *Ann NY Acad Sci* 2005; 1054: 118–23.
106. Schrier SL, Centis F, Verneris M, Ma L, Angelucci E. The role of oxidant injury in the pathophysiology of human thalassemias. *Redox Rep* 2003; 8(5): 241–5.
107. Halliwell B, Gutteridge J. *Free Radicals in Biology and Medicine* (3rd ed.). Oxford University Press. Midsomer Norton, Avon, England.1999.
108. Inoue M, Sato EF, Nishikawa M, Park AM, Kira Y, Imada I, Utsumi K. Mitochondrial generation of reactive oxygen species and its role in aerobic life. *Curr Med Chem* 2003; 10:2495–505.
109. Kakhlon O, Cabantchik ZI. The labile iron pool: characterization, measurement, and participation in cellular processes. *Free Rad Biol Med* 2002; 33:1037–46.
110. Leonard SS, Harris GK, Shi XL. Metal-induced oxidative stress and signal transduction. *Free Rad Biol Med* 2004; 37: 1921–42.
111. Awasthi Y C, Yang Y, Tiwari NK, Patrick B, Sharma A, Li J, et al. Regulation of 4-hydroxynonenal- mediated signaling by glutathione Stransferases. *Free Radic Biol Med* 2004; 37: 607–19.
112. Jones D.P, Carlson JL, Mody VC, Cai J, Lynn MJ, Sternberg P, et al. Redox state of glutathione in human plasma. *Free Radic Biol Med* 2000; 28:625–35.
113. Jayle MF, Moretti J. Haptoglobin: Biochemical, genetic and pathophysiologic aspects. *Prog Hematol* 1962; 3:342-59.

114. Raynes JG, Eagling S, McAdam KP. Acute-phase protein synthesis in human hepatoma cells: Differential regulation of serum amyloid A (SAA) and haptoglobin by interleukin-1 and interleukin-6. *Clin Exp Immunol* 1991; 83:488-91.
115. Rother RP, Bell L, Hillmen P, Gladwin MT. The clinical sequelae of intravascular hemolysis and extracellular plasma hemoglobin: a novel mechanism of human disease. *JAMA* 2005; 293:1653-62.
116. Tabbara IA. Hemolytic anemias: diagnosis and management. *Med Clin North Am.* 1992;76: 649-68.
117. Bowman BH. Haptoglobin. In: Bowman BH, ed. *Hepatic Plasma Proteins*. San Diego, CA: Academic Press; 1993:159-167.
118. Silverman LM, Christenson RH. Amino acids and proteins. In: Burtis CA and Ashwood ER (eds) *Tietz Textbook of Clinical Chemistry*. 2nd edition. W.B. Saunders Co., Philadelphia, 1994. pp 707-708.
119. Braeckman L, Bacquer DD, Delanghe J, Claeys L, Backer GD. Association between haptoglobin polymorphism, lipids, lipoproteins and inflammatory variables. *Atherosclerosis* 1999; 143:383-8.
120. Raugei G, Bensi G, Colantuoni V, Romano V, Santoro C, Costanzo F, et al. Sequence of human haptoglobin cDNA: Evidence that the α and β subunits are coded by the same mRNA. *Nuc Acids Res* 1983; 11:5811-19.
121. Wobeto VP, Zaccariotto TR, Sonati MDF. Polymorphism of human haptoglobin and its clinical importance. *Genetics and Molecular Biology* 2008; 31:602-20.
122. Maeda N. DNA polymorphisms in the controlling region of the human haptoglobin genes: A molecular explanation for the haptoglobin 2-1 modified phenotype. *Am J Hum Genet* 1991; 49:158-66.
123. Connell GE, Smithies O, Dixon GH. Gene action in the human haptoglobins. II. Isolation and physical characterization of alpha polypeptide chains. *J Mol Biol* 1996; 21:225-9.
124. Langlois MR, Delanghe JR. Biological and clinical significance of haptoglobin polymorphism in humans. *Clin Chem* 1996; 42:1589-1600.
125. Frank MM, Lache O, Enav BI, Szafrank T, Levy NS, Ricklis RM. Structure-function analysis of antioxidant properties of haptoglobin. *Blood* 2001; 98:3693- 8.
126. Santoro C, Boccazzi C, Carbonara AO. A simplified procedure for haptoglobin subtyping. *Hum Genet* 1982; 60:287-8.
127. Robson EB, Polani PE, Dart SJ, Jacobs PA, Renwick JH. Probable assignment of the alpha locus of haptoglobin to chromosome 16 in man. *Nature* 1969; 223:1163-5.

128. Koch W, Latz W, Eichinger M, Roguin A, Levy AP, Schomig A. Haptoglobin gene subtyping by restriction enzyme analysis. *Clin Chem* 2003; 49:1937-40.
129. Van der Straten A, Herzog A, Cabezon T, Bollen A. Characterization of human haptoglobin cDNAs coding for alpha 2FS beta and alpha 1S beta Variants. *FEBS* 1984; 168:103-7.
130. Maeda N, Yang F, Barnett DR, Bowman BH, Smithies O. Duplication within the haptoglobin Hp2 gene. *Nature* 1984; 309 :131-5.
131. Yang F, Brune JL, Baldwin WD, Barnett DR, Bowman BH. Identification and characterization of human haptoglobin cDNA. *Proc Natl Acad Sci USA* 1983; 80:5875-9.
132. Hatada S, Grant DJ, Maeda N. An intronic endogenous retrovirus-like sequence attenuates human haptoglobin-related gene expression in an orientation-dependent manner. *Gene* 2003; 319:55-63.
133. Maeda N. Nucleotide sequence of the haptoglobin and haptoglobin-related gene pair. The haptoglobin-related gene contains a retrovirus-like element. *J Biol Chem* 1985; 260:6698-709.
134. Raper J, Fung R, Ghiso J, Nussenzweig V, Tomlinson S. Characterization of a novel trypanosome lytic factor from human serum. *Infect Immun* 1999; 67:1910-16.
135. Smith AB, Esko JD, Hajduk SL. Killing of trypanosomes by the human haptoglobin-related protein. *Science* 1995; 268:284-6.
136. Koda Y, Soejima M, Yoshioka N, Kimura H. The haptoglobin-gene deletion responsible for anhaploglobinemia. *Am J Hum Genet* 1998; 62:245-52.
137. Delanghe JR, Langlois M, De Buyzereache M. Congenital anhaploglobinemia vs. hypohaploglobinemia. *Blood* 1998; 91:3524.
138. Koda Y, Watanabe Y, Soejima M, Shimada E, Nishimura M, Morishita K, et al. Simple PCR detection of haptoglobin gene deletion in anhaploglobinemic patients with antihaploglobin antibody that causes anaphylactic transfusion reactions. *Blood* 2000; 95:1138-43.
139. Soejima M, Koda Y, Fujibara J, Takeshita H. The distribution of haptoglobin-gene deletion (Hp del) is restricted to East Asians. *Transfusion* 2007; 47:1948-50.
140. Teye K, Quaye IKE, Koda Y, Soejima M, Tsuneoka M, Pang H, et al. A-61C and C-101G Hp gene promoter polymorphism are, respectively, associated with anhaploglobinaemia and hypohaploglobinaemia in Ghana. *Clin Genet* 2003; 64:439-43.
141. Constans J, Viau M, Gouaillard C, Clerc A. Haptoglobin polymorphism among Sharian and West African groups. Haptoglobin phenotype determination by radioimmuno-electrophoresis on Hp0 samples. *Am J Hum Genet* 1981; 33:606-16.

142. Bowman BH, Kurosky A. Haptoglobin: The evolutionary product of duplication, unequal crossover, and point mutation. *Adv Hum Genet* 1982; 12:189-261.
143. Rougemont A, Quilici M, Delmont J, Ardisson JP. Is the Hp0 phenomenon in tropical populations really genetic? *Human Heredity* 1980; 30: 201-3.
144. Marini E, Moral P, Petralanda I, Pacheco M, Sandiumenge T, Succa V, et al. Serum protein markers in the Piaroa Indians of Amazonia (Venezuela). *Hum Hered* 1993;43:232-238.
145. Mastana SS, Bernal JE, Onyemelukwe GC, Papiha SS. Haptoglobin subtypes among four different populations. *Hum Hered* 1994; 44:10-13.
146. Zaccariotto TR, Rosim ET, Melo D, Garcia PMD, Munhoz RR, Aoki FH, et al. Haptoglobin polymorphism in a HIV-1-seropositive Brazilian population. *J Clin Pathol* 2006; 59:550-3.
147. Levy AP, Asleh R, Blum S, Levy NS, Miller-Lotan R, Anbinder Y, et al. Haptoglobin: Basic and clinical aspects. *Antioxidants & Redox Signaling* 2010;12: 293-304.
148. Hwang P, Greer J. Interaction between hemoglobin subunits in the hemoglobin-haptoglobin complex. *J Biol Chem* 1980; 255:338-41.
149. Nielsen MJ, Petersen SV, Jacobsen C, Thirup S, Enghild JJ, Graversen JH, et al. A unique loop extension in the serine protease domain of haptoglobin is essential for CD163 recognition of the haptoglobin-hemoglobin complex. *J Biol Chem* 2007; 282:1072-9.
150. Lustbader JW, Arcoletto JP, Birken S, Greer J. Hemoglobin-binding site on haptoglobin probed by selective proteolysis. *J Biol Chem* 1983; 258:1227-34.
151. Moestrup SK, Møller HJ. CD163: a regulated hemoglobin scavenger receptor with a role in the anti-inflammatory response. *Ann Med* 2004; 36: 347-54.
152. Kristiansen M, Graversen JH, Jacobsen C, Sonne O, Hoffman HJ, Law SK, et al. Identification of the haemoglobin scavenger receptor. *Nature* 2001; 409:198-201.
153. Schaer DJ, Schaer CA, Buehler PW, Boykins RA, Schoedon G, Alayash AI, et al. CD163 is the macrophage scavenger receptor for native and chemically modified hemoglobins in the absence of haptoglobin. *Blood* 2006; 107:373-80.
154. Nielsen MJ, Petersen SV, Jacobsen C, Oxvig C, Rees D, Møller HJ, et al. Haptoglobin-related protein is a high-affinity hemoglobin-binding plasma protein. *Blood* 2006; 108:2846-9.
155. Madsen M, Møller HJ, Nielsen MJ, Jacobsen C, Graversen JH, van den Berg T, et al. Molecular characterization of the haptoglobin-hemoglobin receptor CD163: ligand binding properties of the scavenger receptor cysteine-rich domain region. *J Biol Chem* 2004; 279:561-57.

156. Schaer CA, Schoedon G, Imhof A, Kurrer MO, Schaer DJ. Constitutive endocytosis of CD163 mediates hemoglobin-heme uptake and determines the non-inflammatory and protective transcriptional response of macrophages to hemoglobin. *Circ Res* 2006; 99:943-50.
157. Otterbein LE, Soares MP, Yamashita K, Bach FH. Heme oxygenase-1: unleashing the protective properties of heme. *Trends Immunol* 2003; 24: 449-55.
158. Abraham NG, Drummond G. CD163-mediated hemoglobin-heme uptake activates macrophage HO-1, providing an anti-inflammatory function. *Circ Res* 2006; 99:911-4.
159. Mitani K, Fujita H, Kappas A, Sassa S. Heme oxygenase is a positive acute-phase reactant in human Hep3B hepatoma cells. *Blood* 1992; 79: 1255-9.
160. Philippidis P, Mason JC, Evans BJ, Nadra I, Taylor KM, Haskard DO, et al. Hemoglobin scavenger receptor CD163 mediates interleukin-10 release and heme oxygenase-1 synthesis: anti-inflammatory monocyte-macrophage responses in vitro, in resolving skin blisters in vivo, and after cardiopulmonary bypass surgery. *Circ Res* 2004; 94:119-26.
161. Van den Heuvel MM, Tensen CP, Van As JH, Van den Berg TK, Fluitsma DM, Dijkstra CD, et al. Regulation of CD 163 on human macrophages: cross-linking of CD163 induces signaling and activation. *J Leukoc Biol* 1999; 66:858-66.
162. Asleh R, Marsh S, Shilkrut M, Binah O, Guetta J, Lejbkowitz F, et al. Genetically determined heterogeneity in hemoglobin scavenging and susceptibility to diabetic cardiovascular disease. *Circ Res* 2003; 92:1193-1200.
163. Guetta J, Strauss M, Levy NS, Fahoum L, Levy AP. Haptoglobin genotype modulates the balance of Th1/Th2 cytokines produced by macrophages exposed to free hemoglobin. *Atherosclerosis* 2007; 191:48-53.
164. Lee TS, Chau LY. Heme oxygenase-1 mediates the anti-inflammatory effect of interleukin-10 in mice. *Nat Med* 2002; 8:240-6.
165. Strauss M, Levy AP. Regulation of CD163 associated casein kinase II activity is haptoglobin genotype dependent. *Mol Cell Biochem* 2008; 317: 131-5.
166. Langlois M, Delanghe J, Philippe J. Distribution of lymphocyte subsets in bone marrow and peripheral blood is associated with haptoglobin type: binding of haptoglobin to the B-cell lectin CD22. *Eur J Clin Chem* 1997; 35:199-205.
167. Abbas AK, Lichtman AH. *Cellular and Molecular Immunology*. 5th edition. Saunders, Philadelphia, 2003. pp 65-274.
168. Arredouani M, Matthijs P, Hoeyveld V, Kasran A, Baumann H, Ceuppens JL. Haptoglobin directly affects cells and suppresses T helper cell type 2 cytokine release. *Immunol* 2003; 108:144-51.
169. Wonke B. Clinical management of beta-thalassemia major. *Semin Hematol* 2001; 38(4):350-9.

170. Hershko C. Pathogenesis and management of iron toxicity in thalassemia. *AnnNY Acad Sci* 2010; 1202:1-9.
171. Rachmilewitz EA, Giardina PJ. How I treat thalassemia. *Blood* 2011; 118 (13): 3479-88.
172. Perera NJ, Lau NS, Mathews S, Waite C, Ho PJ, Caterson ID. Overview of endocrinopathies associated with β -thalassaemia major. *Intern Med J* 2010; 40(10):689-96.
173. Wood JC, Tyszka JM, Ghugre N, Carson S, Nelson MD, Coates TD. Myocardial iron loading in transfusion-dependent thalassemia and sickle-cell disease. *Blood* 2004; 103:1934-6.
174. Ismaeel H, Cappellini M, Taher A. Chronic transfusion, iron overload and cardiac dysfunction in β thalassemia. *Br J Cardiol* 2008; 15:40-45.
175. Li CK, Chik KW, Lam CWK, To KF, Yu SC, Lee V, et al. Liver disease in transfusion dependent thalassemia major. *Arch Dis Child* 2002; 86:344-47.
176. Iancu TC, Neustein Hb. Ferritin in human liver cells of homozygous β thalassemia. Ultrastructural observations. *Br J Haematol* 1977; 37:527-35.
177. Sher GD, Milone SD, Cameron R, Jamieson FB, Krajden M, Collins AF, et al. Hepatitis C virus infection in transfused patients with β hemoglobinopathies accelerates iron-induced hepatic damage. *Blood* 1993; 82:360a.
178. Tsukamoto H, Horne W, Kamimura S, Niemelä O, Parkkila S, Yiä-Herttula S, et al. Experimental liver cirrhosis induced by alcohol and iron. *J Clin Invest* 1995; 96:620-30.
179. Grundy RG, Woods RA, Savage MO, Evans JPM. Relationship of endocrinopathy to iron chelation status in young patients with thalassemia major. *Arch Dis Child* 1994; 71:128-32.
180. Landau H, Matoth I, Landau-Cordova Z, Goldfarb A, Rachmilewitz EA, Glaser B. Cross-sectional and longitudinal study of the pituitary-thyroid axis in patient with thalassemia major. *Clin Endocrinol* 1993; 38:55-61.
181. Sklar CA, Lew LQ, Yoon DJ, David R. Adrenal function in thalassemia major following long term treatment with multiple transfusions and chelation therapy. Evidence for dissociation of cortisol and adrenal androgen secretion. *Am J Dis Child* 1987; 141:327-30.
182. Kattamis C, Touliatos N, Haidas S, Matsaniotis N. Growth of children with thalassaemia: Effect of different transfusional regimens. *Arch Dis Child* 1970; 45:502-5.
183. Wang C, Tso SC, Todd D. Hypogonadotropic hypogonadism in severe β -thalassemia: Effect of chelation and pulsatile gonadotropin-releasing hormone therapy. *J Clin Endocrinol Metab* 1989; 68:511-6.

184. Werther GA, Matthews RN, Burger HG, Herington AC. Lack of response of non suppressible insulin-like activity to short term administration of human growth hormone in thalassemia major. *J Clin Endocrinol Metab* 1981; 53:806-9.
185. Siemons LJ, Mahler CH. Hypogonadotropic hypogonadism in hemochromatosis: Recovery of reproductive function after iron depletion. *J Clin Endocrinol Metab* 1987; 65:585-7.
186. Wonke B. Clinical Management of β -Thalassemia Major. *Semin Hematol* 2001; 38:350-9.
187. Shamsian BS, Arzanian MT, Shamshiri AR, Alavis S, Khojasteh O. Frequency of red cell alloimmunization in patients with β -major thalassemia in an Iranian referral hospital. *Iran J Pediatr* 2008; 18(2):149-53.
188. Singer ST, Wu V, Mignacca R, Kuypers FA, Morel P, Vichinsky EP, et al. Alloimmunization and erythrocyte autoimmunization in transfusion-dependent thalassemia patients of predominantly Asian descent. *Blood* 2000; 96(10):3369-73.
189. Salama MA, Sadek NA, Hassab HM, Abadeer AF, Mikhael IL. Erythrocyte autoantibodies and expression of CD59 on the surface of red blood cells of polytransfused patients with beta-thalassemia major. *Br J Biomed Sci* 2004; 61:88-92.
190. Ameen R, Al-Shemmari S, Al-Humood S, Chowdhury RI, Al-Eyaadi O, Al-Bashir A, et al. RBC alloimmunization and autoimmunization among transfusion-dependent Arab thalassemia patients. *Transfusion* 2003; 43(11):1604-10.
191. Reeder BJ, Hider RC, Wilson MT. Iron chelators can protect against oxidative stress through ferryl heme reduction. *Free Radic Biol Med* 2008; 44: 264–73.
192. Borgna-Pignatti C, Cappellini MD, De Stefano P, Del Vecchio GC, Forni GL, Gamberini MR, et al. Cardiac morbidity and mortality in deferoxamine- or deferiprone-treated patients with thalassemia major. *Blood* 2006; 107(9):3733-7.
193. Telfer PT, Warburton F, Christou S, Hadjigavriel M, Sitarou M, Kolnagou A, et al. Improved survival in thalassemia major patients on switching from desferrioxamine to combined chelation therapy with desferrioxamine and deferiprone. *Haematologica* 2009; 94(12):1777-8.
194. Modell B, Khan M, Darlison M. Survival in β -thalassaemia major in the UK: data from the UK thalassaemia register. *Lancet* 2000; 355(9220):2051-2.
195. Giardina PJ, Grady RW. Chelation therapy in β -thalassemia: the benefits and limitations of desferrioxamine. *Semin Hematol* 1995; 32(4):304-12.
196. Cappellini MD. Overcoming the challenge of patient compliance with iron chelation therapy. *Semin Hematol* 2005; 42(1):S19-21.

197. Hider RC, Choudhury R, Rai BL, Dehkordi LS, Singh S. Design of orally active iron chelators. *Acta Haematol* 1996; 95(1):6-12.
198. Olivieri NF, Brittenham GM, Matsui D, Berkovitch M, Blendis LM, Cameron RG, et al. Iron-chelation therapy with oral deferiprone in patients with thalassemia major. *N Engl J Med* 1995; 332(14): 918-22.
199. Taher AT, Sheikh-Taha M, Sharara A, Inati A, Koussa S, Ellis G, et al. Safety and effectiveness of 100 mg/kg/day deferiprone in patients with thalassemia major: a two-year study. *Acta Haematol* 2005; 114(3):146-9.
200. Grady RW, Hilgartner MW, Giardina PJ. Deferiprone: its efficacy relative to that of desferal. *Blood* 1996; 88:310a.
201. Kidson-Gerber G, Lindeman R. Adherence to desferrioxamine and deferiprone and the impact of deferiprone co-prescription in thalassemia major patients: does the addition of deferiprone improve adherence? *Br J Haematol* 2008; 142(4):668-80.
202. Anderson LJ, Wonke B, Prescott E, Holden S, Walker JM, Pennell DJ. Comparison of effects of oral deferiprone and subcutaneous desferrioxamine on myocardial iron concentrations and ventricular function in beta thalassemia. *Lancet* 2002; 360(9332):516-20.
203. Cohen AR, Galanello R, Piga A, De Sanctis V, Tricta F. Safety and effectiveness of long-term therapy with the oral iron chelator deferiprone. *Blood* 2003; 102(5):1583-7.
204. Galanello R, Piga A, Alberti D, Rouan M-C, Bigler H, Sechaud R. Safety, tolerability, and pharmacokinetics of ICL670: a new orally active iron chelating agent in patients with transfusion-dependent iron overload due to beta thalassemia. *J Clin Pharmacol* 2003; 43(6):565-72.
205. Piga A, Galanello R, Forni GL, Cappellini MD, Origa R, Zappu A, et al. Randomized phase II trial of deferasirox (Exjade, ICL670), a once-daily, orally administered iron chelator, in comparison to deferoxamine in thalassemia patients with transfusional iron overload. *Haematologica* 2006; 91(7):873-80.
206. Cappellini MD, Cohen A, Piga A, Bejaoui M, Perrotta S, Agaoglu L, et al. A phase 3 study of deferasirox (ICL670), a once-daily oral iron chelator, in patients with beta-thalassemia. *Blood* 2006; 107(9):3455-62.
207. Taher A, El-Beshlawy A, Elalfy MS, Al Zir K, Daar S, Habr D, et al. Efficacy and safety of deferasirox, an oral iron chelator, in heavily iron-overload patients with beta-thalassemia: the ESCALATOR study. *Eur J Haematol* 2009; 82(6):458-65.
208. Pennell DJ, Porter JB, Cappellini MD, El-Bashlawy A, Chan LL, Aydinok Y, et al. Efficacy of deferasirox in reducing and preventing cardiac iron overload in β -thalassemia. *Blood* 2010; 115(12) 2364-71.

209. Cappellini MD, Bejaoui M, Agaoglu L, Canatan D, Capra M, Cohen A, et al. Iron chelation with deferasirox in adult and pediatric patients with thalassemia major: efficacy and safety during 5 years' follow-up. *Blood* 2011; 118(4):884-93.
210. Porter JB. Practical management of iron overload. *Br J Haematol* 2001; 115: 239 – 53.
211. Gattermann N. Guidelines on iron chelation therapy in patients with myelodysplastic syndromes and transfusional iron overload. *Leuk Res* 2007; 31(3):10–5.
212. Aydinok Y, Evans P, Terzi A, Cetiner N, Porter JB. Randomised, prospective evaluation of iron balance, chelation efficiency, urine excretion and NTBI progression with deferiprone (DFP) or deferoxamine (DFO) monotherapy or with combined DFP plus DFO. *Blood* 2005;106 (11 Pt 1):2698.
213. Lewis SM, Bain BJ, Bates I. In:Dacie and Lewis Practical Hematology. 11th ed. Churchill Livingstone Elsevier, Philadelphia. 2011, pp.26-54.
214. Chui DHK SM. Laboratory Diagnosis of Hemoglobinopathies and Thalassemias. In: Hoffman R BJE, Shattil SJ, Furie B, Silberstein LE, McGlave P, Heslop HE, ed. *Hoffman: Hematology: Basic Principles and Practice*. Edinburgh: Churchill Livingstone; 2008.
215. Looker AC, Gunter EW, Johnson CL. Methods to assess iron status in various NHANES Surveys. *Nutrition Reviews* 1995; 53:9: 246-54.
216. Ikram N, Hassan K, Younas M, Amanat A . Ferritin Levels in Patients of Beta Thalassemia Major. *Intern J Pathol* 2004; 2(2):71-4.
217. Pepys MB. C-reactive protein fifty years on. *Lancet* 1981; 21 ;(1):653–57.
218. Lapierre Y, Rigal D, Adam J, Josef D, Meyer F, Greber S, et al. The gel test: a new way to detect red cell antigen-antibody reactions. *Transfusion* 1990; 30(2):109-13.
219. Burtis CA, Ashwood ER, Bruns DE. *Tietz Fundamentals of Clinical Chemistry*. 6th ed Elsevier Saunders Company, St Lous 2008, pp.286-316.
220. Draper HH, Hadley M. (1990): Malondialdehyde determination as index of lipid peroxidation. *Methods Enzymol* 1990; 186: 421-5.
221. Koch W, Latz W, Eichinger M, Roguin A, Levy AP, Andrew P , et al. Genotyping of the common haptoglobin Hp 1/2 polymorphism based on PCR. *Clin Chem* 2002; 48:1377– 82.
222. Leslie E, Geoffrey J, James M. Statistical analysis. In: Interpretation and uses of medical statistics (4th ed). Oxford Scientific Publications. 1991;411-6.
223. Kirkpatrick LA, Feeney BC. A simple guide to IBM SPSS statistics for version 20.0. Student ed. Belmont, Calif : Wadsworth, Cengage Learning. 2013;115.

224. Skordis N. The growing child with Thalassaemia. *J Pediatr Endocrinol Metab* 2006; 19: 467-9.
225. Salih MK, Mosawy W. Evaluation of some consequences of thalassemia major in splenectomized and non splenectomized Iraqi patients. *Int J Pharm Pharm Sci* 2013; 5:385-88.
226. Pemde KH, Chandra J, Gupta D, Singh V, Sharma R, Dutta AK. Physical growth in children with transfusion-dependent thalassemia. *Pediatric Health, Medicine and Therapeutics* 2011;2: 13–19.
227. De Sanctis V, Roos M, Gasser T, Fortini M, Raiola G, Galati MC. Impact of long-term iron chelation therapy on growth and endocrine functions in Thalassaemia. *J Pediatr Endocrinol Metab* 2006;19:471-80.
228. Olivieri NF, Koren G, Harris J, Khattak S, Freedman MH, Templeton DM, Bailey JD, Reilly BJ. Growth failure and bony changes induced by deferoxamine. *Am J Pediatr Hematol Oncol.* 1992;14(1):48-56.
229. Galanello R, Melis MA, Ruggeri R, Addis M, Scalas MT, Maccioni L, et al. Beta⁰ thalassemia trait in Sardinia. *Hemoglobin* 1979; 3:33–46.
230. Galanello R, Origa R. Beta-thalassemia. *Orphanet J Rare Dis* 2010; 5:5-11.
231. Paunipagar PV, Vaidya SM, Singh CM. Changing pattern of Hb electrophoresis and Hb A2 level in β thalassemia major. *Indian J Prev Soc Med.* 2010; 41:148-50.
232. Prokop O, Kohler W. Haptoglobins act similar to antibodies. *Zentralbl Gynakol* 1979;101: 1111-6.
233. Arinsburg SA, Skerrett DL, Kleinert D, Giardina PJ, Cushing MM. The significance of a positive DAT in thalassemia patients. *Immunohematology* 2010; 28(3):87-91.
234. Hok-Kung Ho, Shau-Yin Ha, Chun-Kit Lam, Godfrey C, Chan F, Tsz-Leung Lee, et al. Alloimmunization in Hong Kong southern Chinese transfusion-dependent thalassemia patients. *Blood* 2001;97(12):3999-4000.
235. Park MY, Park J, Yunjeong JO, Kim HS, Shin CK, Won SI, et al. Prolonged Extreme Thrombocytosis in a Postsplenectomy Patient with Hereditary Spherocytosis. *Korean J Hematol* 2009; 44:298-303.
236. Hutin Y, Kitler EM, Dore JG, Perz FJ, Armstrong LG, Dusheiko G. Global burden of disease for hepatitis C. *Pharmacol* 2004;44: 20-5
237. Shepard CW, Finelli L, Alter M. Global epidemiology of hepatitis C virus infection. *Lancet Infect Dis* 2005; 5:558-68.
238. Louagie HK, Brouwer JT, Delanghe JR, Buyzere ML, Leroux-Roels GG. Haptoglobin polymorphism and chronic hepatitis C. *J Hepatol* 1996;25(1):10-14.

239. Angelucci E , Pilo F. Treatment of hepatitis C in patients with thalassemia. *Hematologica* 2008; 93(8):1121-23.
240. Kasvosve I, Gomo ZA, Gangaidzo IT, Mvundura E, Saungweme T, Moyo AV, et al. Reference range of serum haptoglobin is haptoglobin phenotype-dependent in blacks. *Clinica Chimica Acta* 2000;296:163-70.
241. Imrie H, Freya J, Fowkes I, Michon P, Tavul L, Hume JC , et al. Haptoglobin levels are associated with haptoglobin genotype and +/- thalassemia in a malaria –endemic area. *Am J Trop Med* 2006; 74(6): 965–71.
242. Van VH, Langlois M, Delanghe J. Haptoglobin polymorphisms and iron homeostasis in health and in disease. *Clin Chim Acta* 2004;345:35–42.
243. Langlois MR, Martin ME, Boelaert JR, Beaumont C, Taes YE, De Buyzere ML, et al. The haptoglobin 2-2 phenotype affects serum markers of iron status in healthy males. *Clin Chem* 2000;46:1619–25.
244. Carter K, Worwood M. Haptoglobin: a review of the major allele frequencies worldwide and their association with diseases. *Int J Lab Hematol.* 2007;29:92-110.
245. Kihm AJ, Kong Y, Hong W, Russell JE, Rouda S, Adachi k, et al. An abundant erythroid protein that stabilizes free alpha hemoglobin. *Nature* 2002;417: 758-63.
246. Na N , Delanghe J, Taes Y, Tork M, Beayens W, Jin OY. Vitamin C concentrations is influenced by haptoglobin polymorphism and iron status in Chinese. *Clinica Chimica Acta* 2006;365:319-24.
247. Levy AP, Rouin A, Marsh S, Nakhoul FM, Skorecki K. Haptoglobin phenotype and vascular complications in diabetes. *NEJM* 2000;343:369-70.
248. Wagner L, Gessl A, Baumgartner Parzer S, Base W, Pasternack MS. Haptoglobin phenotyping by newly developed monoclonal antibodies. Demonstration of haptoglobin uptake into peripheral blood neutrophils and monocytes. *Immunol* 1996;156:1989-96.
249. ElGhmati SM, Van Hoeyveld EM, Van Strijp JG, Ceuppens JL, Stevens EA. Identification of haptoglobin as an alternative ligand for CD11b/CD18. *J Immunol* 1996;156:2542-52.
250. Nielsen MJ, Moestrup SK. Receptor targeting of hemoglobin mediated by the haptoglobins: roles beyond heme scavenging . *Blood* 2009;114:764-71.
251. Reiter CD, Wang XD, Tanus-Santos JE, Hogg N, Cannon RO , Schechter AN, et al. Cell-free hemoglobin limits nitric oxide bioavailability in sickle-cell disease. *Nat Med* 2002;8:1383-89.
252. Gueye MP, Glasser N, Ferard G, Lessinger J. Influence of human haptoglobin polymorphism on oxidative stress induced by free hemoglobin on red blood cells. *Clin Chem Med* 2006;44(5):542-47.

253. Asleh R, Guetta J, Litman SK, Lotan RM, Levy AP. Haptoglobin genotype- and diabetes-dependent differences in iron-mediated oxidative stress in vitro and in vivo. *Circ Res* 2005;96:435–41.
254. Porter JB. Advances in the monitoring and treatment of iron overload. *Hematology* 2005; 1: 60-64.
255. Van VH, Langlois MR, DelangheJR, Horsmans Y, Michielsen P, Henrion J, et al. Haptoglobin phenotype 2-2 over representation in Cys282Tyr hemochromatotic patients. *J Hepatol* 2001; 35:707–711.
256. Haggag AA, Abd elfatah M. Therapeutic value of silymarin as iron chelator in children with beta thalassemia with iron overload. *J Leukemia* 2014;2 (1);132.
257. Dröge W. Free radicals in the physiological control of cell function. *Physiol Rev* 2002;82 (1):47-95.
258. Blum S, Asaf R, Guetta J, Miller L, Asleh R, Kremer R, et al. Haptoglobin genotype determines myocardial infarct size in diabetic mice. *J Am Coll Cardiol* 2007;49 (1):82-7.
259. Awadallah MS, Nimer AN, Atoum FM, Saleh AS. Association of haptoglobin phenotypes with ceruloplasmin ferroxidase activity in β -thalassemia major. *Clin Chim Acta* 2011;412:975-79.
260. Chekir KA, Laradi S, Ferchichi S, Khelil HA, Feki M, Amri F, et al. Miled oxidant, antioxidant status and metabolic data in patients with beta-thalassemia. *Clin Chim Acta* 2003; 338(1-2):79-86.
261. Ludwiczek S, Aigner E, Theurl I, Weiss G. Cytokine-mediated regulation of iron transport in human monocytic cells. *Blood* 2003; 101(10):4148-54.
262. Papanikolaou G, Tzilianos M, John I, Bogdanos D, Tsimirika K, Farlane MJ, et al. Hcpidin in iron overload disorders. *Blood* 2005; 105(10): 4103–05.
263. Kohgo Y, Ikuta K, Ohtake T, Torimoto Y, Kato J. Body iron metabolism and pathophysiology of iron overload. *Int J Hematol* 2008; 88: 7–15.
264. Dobryczycka w. Haptoglobin in the new millennium. *Adv Clin Exp Med* 2004; 13: 3–18.
265. Koda Y, Watanabe Y, Soejima M, Shimada E, Nishimura M, Morishita K, et al. Simple PCR detection of haptoglobin gene deletion in anhaptoalbuminemic patients with anti-haptoglobin antibody that causes anaphylactic transfusion reactions. *Blood* 2000; 95: 1138–43.
266. Shimada E, Tadokoro K, Watanabe Y, Ikeda K, Niihara H, Maeda I, et al. Anaphylactic transfusion reactions in haptoglobin-deficient patients with IgE and IgG haptoglobin antibodies. *Transfusion* 2002; 42:706–73.

267. Standing S, Price CP. A kinetic method for the determination of haptoglobin as haemoglobin binding capacity. *Clin Chim Acta* 1976;66: 393-403.
268. Kickler TS, Fong PF, Johnson GF, Solomon HM. Kinetic determination of serum haptoglobin with a centrifugal analyzer. *Clin Chem* 1976;22:1962-7.
269. Shim BS, Jue DM. Simple determination of haptoglobin level in serum. *Clin Chim Acta* 1984;136:145-53.
270. Van Rn HM, Kruit WJH, Schrijver I. Haptoglobin typing: is it clinically necessary for a reliable determination of haptoglobin with the single radial immunodiffusion technique? *J Clin Chem Clin Biochem* 1984; 22: 109-12.
271. Van Lente F, Marchand A, Galen RS. Evaluation of a nephelometric assay for haptoglobin and its clinical usefulness. *Clin Chem* 1979; 25: 2007-10.
272. Smithies O. Zone electrophoresis in starch gels: group variations in the serum proteins of normal human adults. *Biochem J* 1995; 61(4): 629-41.
273. Alonso A, Visedo G, Sancho M, Fernandez-Piqueras J. Haptoglobin subtyping by isoelectric focusing in miniaturized polyacrylamide gels rehydrated in presence of 2-mercaptoethanol. *Electrophoresis* 1990;11(4) :321-24.
274. Delanghe J, Allcock K, Langlois M, Claeys L, De Buyzere M, Fast determination of haptoglobin phenotype and calculation of hemoglobin binding capacity using high pressure gel permeation chromatography. *Clinica Chimica Acta* 2000; 291:43-51.
275. Levy NS, Levy AP. Elisa for determination of the haptoglobin phenotype. *Clin Chem* 2004; 50 (11): 2148-50.
276. Ko HD, Chang EH, Kim ST, Song YE, Park K, Song J, et al. A review of haptoglobin typing methods for disease association study and preventing anaphylactic transfusion reaction. *BioMed Research International*. <http://dx.doi.org/10.1155/2013/390630>.

الملخص العربي

تعتبر متلازمة الثلاسيميا خلا موروثا في الهيموجلوبين و ناتجا عن الانتاج غير المتوازن لسلاسل الجلوبين المكونة لجزئى الهيموجلوبين مما يؤدي الي الزيادة النسبية لاحداها و ينتج عن ذلك انيميا تكسيرية مزمنة تتراوح شدتها على نطاق واسع بين اعراض طفيفة و اشكال قاتلة. وراثيا يعتبر مرض الثلاسيميا المرض الوراثي الاكثر شيوعا في العالم لفقر الدم التكريري الوراثي حيث يقدر أن حوالي ١,٥٪ من سكان العالم (٨٠ إلى ٩٠ مليون نسمة) حاملين للبيتا ثلاسيميا ، و يولد سنويا حوالي ٦٠٠٠٠ فرد تظهر عليهم الأعراض ، الغالبية العظمى في العالم النامي و في مصر تتراوح نسبة الحاملين له بين ٥,٣ الى ١٠٪.

يعتمد مرضي الثلاسيميا الكبرى بيتا على النقل المنتظم لكرات الدم الحمراء مدي الحياة ، وبالرغم من ان هذا البروتوكول القياسي لنقل الدم ساهم بنسبة كبيرة في اطالة و تحسين نمط الحياة لمرضي الثلاسيميا الكبرى، الا انه يؤدي الي زيادة نسبة الحديد بالدم مما يؤثر علي معظم اعضاء الجسم و يؤدي الي مضاعفات خطيرة قد تنتهي بالوفاة.

يعتبر الجهد التاكسدي الية هامة في تقدم و تقاوم الثلاسيميا الكبرى و إسهاماته في تقدم المرض مفهوم جزئيا فقط

كما اكتسبت عملية توليد الأوكسجين الحر أهمية بسبب دورها في الآلية المرضية للكثير من العمليات المرضية وأثرها على معدلات الوفيات والإصابة بالأمراض ، كما ان الجذور الحرة الأوكسجين تسبب اكسدة للدهون والمنتج النهائي هو المالوندايالدهيد.

و قد استخدم عقار الديسفرال لكرب الحديد لعدة عقود في المرضى الذين يعانون من مرض الثلاسيميا، نظراً لقدرته على تثبيط نشاط الأوكسدة والاختزال من الفلزات الانتقالية من خلال عملية إزالة الحديد.

الهابتوجلوبين (موثق الهيموجلوبين) هو بروتين مرحلة حادة يزيل الهيموجلوبين في حالة تكسير الدم داخل الأوعية أو خارجها ، ويقبل من إمكانية الأوكسدة للهيموجلوبين الحر ٠ في الانسان تم تحديد ثلاثة انماط وراثية اساسية للهابتوجلوبين وهي HP1-1,HP2-2,HP2-1 الذي يحدده الاليلات HP1,HP2.

ان الوظائف الفريدة والمميزة لكل نمط وراثي جعلتنا ندقق النظر في اهمية تعدد النمط الجيني للهابتوجلوبين حيث انه في الآونة الأخيرة، أثبتت العديد من الاختلافات الوظيفية بين انماط الهابتوجلوبين أن لها عواقب بيولوجية وسريرية مهمة. ويرتبط تعدد الأشكال للهابتوجلوبين مع انتشار وتطور للعديد من الأمراض الالتهابية، بما في ذلك العدوى، وتصلب الشرايين، واضطرابات المناعة الذاتية.و يتم تفسير هذه الآثار بانها تعتمد على النمط الظاهري لتعديل الجهد التاكسدي وتصنيع البروستاجلاندين. وتم تأكيد دور الهابتوجلوبين المضاد للأوكسدة ، واعتماده على النمط الظاهري لمنع الضرر التأكسدي المحتمل الناجم عن الهيموجلوبين المتحرر و تحرير الحديد خلال الايض.

وقد اجريت هذه الدراسة لمعرفة تأثير تائثر التنوع الجيني للهابتوجلوبين على المظهر الاكلينيكي المتباين في مرضى انيميا البحر المتوسط - بيتا و علاقته بزيادة الحديد و الجهد التاكسدي.

اجريت الدراسة على خمسين مريض بيتا ثلاسيميا قد سبق تشخيصهم و تتراوح اعمارهم بين ١٢ و ٢٠ عاما و يتلقون نقل دم بصورة منتظمة و عقار الديسفيرال لعلاج ارتفاع نسبة الحديد بالدم .

و قد تم استبعاد المرضى الذين ظهر عليهم اعراض عدوى نشطة.

و شملت الدراسة ايضا مجموعة ضابطة للبيانات من خمسة و عشرين شخص اصحاء المظهر تتراوح اعمارهم بين ١٣ و ٢٠ عاما.

المرضى و طرق البحث:

تم عمل الاتي للحالات

تسجيل البيانات التاريخية للمرضي بما في ذلك التاريخ الشخصي والحالي والماضي والعائلي والدوائى.

الفحص الاكلينيكي الباطني

اختبارات معملية و تشمل

صورة دم كاملة مع الفحص المجهرى و عد الخلايا الشبكية قبل نقل الدم

اختبار مستوى بروتين سى التفاعلي (للكشف عن اى عدوى نشطة)

اختبار كومبس (المناعة الذاتية كسبب لانحلال الدم)

قياس مستوى الحديد و نسبة الفريتين(مخزون الحديد) و تشبع الترانسفيرين في مصل الدم

قياس مستوى الهابتوجلوبين (موتق الهيموجلوبين) فى مصل الدم

قياس مستوى المألون دايالدهيد في مصل الدم

ابحاث وراثية (تفاعل البوليمراز المتكرر) لتحديد الطرز الجينية المتعددة للهابتوجلوبين و ذلك عن طريق استخلاص الحامض النووى من كرات الدم البيضاء

النتائج:

وتؤكد البيانات من دراستنا أن انخفاض مستوى الهيموجلوبين في مجموعة الثلاسيميا مصحوبا بانخفاض في عدد الكريات الحمراء وتناقص قيم مؤشراتهما المحددة (MCH,MCV,PCV)

واظهرت النتائج ارتفاع مستوى الحديد و الفريتين فى مصل الدم لمرضى الثلاسيميا مقارنة بالمجموعة الضابطة و كانت هذه الزيادة ذات دلالة احصائية

وكشفت الدراسة أن ٣٢% من مرضى الثلاسيميا ايجابيون لفيروس التهاب الكبدى ج و هى نسبة اعلى من نسبة انتشار المرض المبلغ عنها في مصر (١٥-٢٠%)

اظهرت الدراسة ان ١٦% من المرضى كان اختبار كومبس لديهم ايجابى ويعزى ذلك جزئيا إلى عدم وجود فحص روتينى للانماط الشكلية طفيفة الحدوث فى بنوك الدم لدينا

فى هذه الدراسة تم العثور على ارتباط ذو دلالة احصائية بين اختبار كومبس الايجابى و انخفاض مستوى الهابتوجلوبين فى المصل لديهم (٠,٠١٧) الذى يتم استهلاكه لتوثيق الهيموجلوبين المتحرر

من ناحية أخرى، يمكن أن يعزى انخفاض مستويات الهابتوجلوبين فى المصل فى مرضى الثلاسيميا إلى وجود أشكال متعددة من الجينات للهابتوجلوبين. ونتيجة لذلك، النمط الوراثى HP1-1 ينتج عنه مستوى أعلى من هابتوجلوبين فى المصل بينما الانماط الوراثية HP2-1 و HP2-2 ترتبط مع انخفاض مصل هابتوجلوبين لمستويات تقترب من الدلالة الإحصائية.

٢

فى هذه الدراسة، كان ٥٦% المرضى لديهم النمط الجيني الوراثةى HP2-2 يليه HP2-1

بينما فى المجموعة الحاكمة كان الطرز الجينى HP2-1 مهيم .

كما كشفت الدراسة أن مرضى الثلاسيميا مع النمط الجينى HP2 2 وجد لديهم اعلى مستوى من الفيريتين فى المصل

فى هذه الدراسة، تم العثور على مستوى أعلى بكثير من المألوندايالدهيد فى المرضى عن المجموعة الضابطة، و هو علامة على زيادة الجهد التاكسدى فى المرضى مقابل عنصر التحكم (P < 0.001)، كما وجد ان مجموعة المرضى لديهم النمط الجينى HP2-2 (P = 0.056) مقارنة بالأشكال الأخرى.

الاستنتاج:

من هذه الدراسة نستنتج ان مرضى التلاسيميا يعانون من خطر زيادة الجهد التاكسدى.

اختلاف النمط الجينى والتعددية الشكلية للهابتوجلوبين له اثر كبير على الجهد التاكسدى فى مرضى التلاسيميا

مرضى التلاسيميا ذوى النمط الجينى HP2-2 هم اكثر عرضة للجهد التاكسدى الناتج عن زيادة الحديد عن الانماط الوراثة الاخرى .

الهابتوجلوبين يعمل كمضاد للاكسدة بحكم قدرته على توثيق الهيموجلوبين و منع الاكسدة و تلف الانسجة.

تواتر عمليات نقل الدم التي تعطي شهريا على ما يبدو غير كافية حيث ان ٩٨٪ من المرضى لديهم تدنى فى نسبة الهيموجلوبين قبل نقل الدم.

من حيث مستوي الفريتين فى مصل الدم حوالى ٩٤٪ من المرضى بحاجة الى اعادة النظر فى نظامهم العلاجى لكرب الحديد من الجسم.

التوصيات:

ضرورة تحديد فصائل الدم باستفاضة لمرضى التلاسيميا.

توصى الدراسة بضرورة تعيين النمط الجينى للهابتوجلوبين فى مرضى التلاسيميا للعناية أكثر بحاملى النمط HP2-2 من حيث ادخال عدة كلابات للحديد و اضافة مضادات الأكسدة لهم لتقليل الجهد التاكسدى و بالتالى المضاعفات الناتجة عنه.

عمل تحليل المالوندايالهيديد علي الاقل مرة كل عام.

النظر في ارتفاع معدل انتشار فيروس التهاب الكبد ج بين المرضى و تحسين الية فحص اكياس الدم خاصة لفيروس ج.

تأثير التعدد الجيني للهابتوجلوبين على المظهر الاكلينيكي المتباين
فى مرضى انيميا البحر المتوسط - بيتا و علاقته بزيادة الحديد
والجهد التاكسدى

رسالة علمية

مقدمة الى معهد البحوث الطبية-جامعة الاسكندرية
استيفاء للدراسات المقررة للحصول على درجة

الدكتوراة فى طب وباثولوجيا امراض الدم
مقدمة من

خالد سعد احمد سالم

معهد البحوث الطبية
جامعة الاسكندرية

٢٠١٤

تأثير التعدد الجيني للهابتوجلوبين على المظهر الاكلينيكي المتباين
فى مرضى انيميا البحر المتوسط - بيتا و علاقته بزيادة الحديد
والجهد التاكسدى

مقدمة من

خالد سعد احمد سالم

للحصول على درجة

الدكتوراه فى طب وباثولوجيا امراض الدم

موافقون

لجنة المناقشة والحكم على الرسالة

.....

أ.د/ لىلى السيد زيادة
أستاذ أمراض الدم
معهد البحوث الطبية
جامعة الإسكندرية

.....

أ.د/ نادية على صادق
أستاذ أمراض الدم
معهد البحوث الطبية
جامعة الإسكندرية

.....

أ.د/ نيفين احمد عبد العال قاسم
أستاذ الباثولوجيا الإكلينيكية
كلية الطب
جامعة عين شمس

.....

أ.د.هدى محمد ابو الفتوح حساب
أستاذ طب الأطفال
كلية الطب
جامعة الإسكندرية

المشرفون

موافقون

الأستاذة الدكتورة ليلي السيد زيادة
أستاذ أمراض الدم
معهد البحوث الطبية - جامعة الاسكندرية

الأستاذة الدكتورة نادية على صادق
استاذ امراض الدم
معهد البحوث الطبية - جامعة الاسكندرية

الدكتور ماهر عبد النبي كامل
استاذ مساعد بقسم الكيمياء الحيوية
معهد البحوث الطبية - جامعة الاسكندرية

الدكتورة علا على بلبع
استشارى مساعد بقسم امراض الدم
معهد البحوث الطبية - جامعة الاسكندرية